A detailed history of Citigroup Inc transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Citigroup Inc holds 53,730 shares of RGLS stock, worth $91,341. This represents 0.0% of its overall portfolio holdings.

Number of Shares
53,730
Previous 14,165 279.32%
Holding current value
$91,341
Previous $25,000 236.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.46 - $1.9 $57,764 - $75,173
39,565 Added 279.32%
53,730 $84,000
Q2 2024

Aug 12, 2024

SELL
$1.79 - $2.8 $3 - $5
-2 Reduced 0.01%
14,165 $25,000
Q1 2024

May 10, 2024

BUY
$1.13 - $2.88 $13,609 - $34,686
12,044 Added 567.31%
14,167 $40,000
Q4 2023

Feb 09, 2024

BUY
$1.21 - $1.44 $2,568 - $3,057
2,123 New
2,123 $2,000
Q2 2022

Aug 10, 2022

BUY
$1.6 - $3.4 $12 - $27
8 New
8 $0

Others Institutions Holding RGLS

About Regulus Therapeutics Inc.


  • Ticker RGLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,634,400
  • Market Cap $24.9M
  • Description
  • Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...
More about RGLS
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.